Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration
Bristol-Myers Squibb Company (NYSE: BMY) and The University of Texas MD Anderson Cancer Center
today announced a novel clinical research collaboration to evaluate
multiple immunotherapies, including Opdivo (nivolumab), Yervoy
(ipilimumab) and three early-stage clinical immuno-oncology assets from
Bristol-Myers Squibb, as potential treatment options for acute and
chronic leukemia as well as other hematologic malignancies.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news
More News: Acute Leukemia | Cancer | Cancer & Oncology | Chronic Leukemia | Hematology | Leukemia | Texas University | Yervoy